On 8 April 2021, Dr John Liddicoat (LML Senior Research Associate) participated in a panel discussion on novelty and second medical use patents.
Hosted by Life Sciences Intellectual Property Review, ‘Why patent protection is Key to Commercialising Repurposed Drugs’ was a roundtable event which sought to discuss how stakeholders might use patents maximise their returns on repurposed drugs. Discussion focused on overcoming three barriers to patent protection in particular: the issue of novelty; obviousness rejections and the use of “unexpected results; and the distinctions between “composition of matter” patents and “method of use” patents.
Further information can be found here.